clinical trial · NCT03728933
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
UCB Biopharma SRL·phase3·terminated·n = 23
Restless Legs SyndromeRotigotine 1 milligram/24 hoursRotigotine 2 milligram/24 hoursPlacebo
brief summary
The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.
started
Dec 20, 2018
primary completion
Jul 25, 2022
completion
Jul 25, 2022
last updated
Oct 26, 2023
official title
A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol